Has Volker Haase received payments from drug or device companies?

Yes. Drug and device makers reported $123,100 in general payments to Volker Haase across 91 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Volker Haase did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Volker Haase come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Volker Haase

Nephrology · Nashville, TNNPI 1457386591

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $83,553 of the $123,100 with a category attached, or 67.9%. 10 manufacturers reported payments, led by AstraZeneca at 41.0% of the total. Reporting peaked in 2019 at $49,131 and has fallen 95.7% since, to $2,113 in 2023. Among nephrology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,100in general payments, 2019–2025

Across 91 payments — averaging $1352.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$50K
GSK$24K
Astrazeneca UK Limited$13K
Akebia Therapeutics Inc$12K
Astrazeneca AB$9K
Otsuka America Pharmaceutical, Inc.$5K
plus $10K from 4 others

$145,501in research payments, 2019–2025

Across 2 payments — averaging $72,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Akebia Therapeutics Inc$146K

What the payments were for

Consulting fees$83,55368%
Speaking & faculty fees$14,60012%
Travel & lodging$23,36419%
Food & beverage$1,4231%
Education$1600%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	47	$50,498
GSK	7	$24,482
Astrazeneca UK Limited	10	$12,531
Akebia Therapeutics Inc	6	$12,201
Astrazeneca AB	12	$9,346
Otsuka America Pharmaceutical, Inc.	3	$4,505
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$4,420
Rockwell Medical, Inc.	1	$2,800
Incyte Corporation	3	$2,243
Mallinckrodt Enterprises LLC	1	$75

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LOKELMA$14,702
TRIFERIC$2,800

How this compares

$123,100 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee →

Other nephrology in Nashville

Jamie DwyerNashville$461K
Talat IkizlerNashville$93K
Julia LewisNashville$87K
Osama El ShamyNashville$87K
Thomas GolperNashville$26K
Anthony LangoneNashville$23K
James LutherNashville$20K
Jeffrey HymesNashville$19K
Roy ZentNashville$17K
Alfred GeorgeNashville$16K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →